Medivir (LSE:0GP7) - Hisse Senedi Fiyatı, Haberler ve Analizler

0GP7 Stoklara Genel Bakış

A pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. Daha fazla detay

0GP7 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 58.84% oranında artması öngörülüyor

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( SEK8M )

Hisse senetleri oldukça likit değildir

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

Medivir AB (publ) Rakipler

Oncimmune Holdings

AIM:ONC

UK£17.2m

OptiBiotix Health

AIM:OPTI

UK£12.2m

Tissue Regenix Group

AIM:TRX

UK£40.6m

Aptamer Group

AIM:APTA

UK£6.5m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Medivir
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	SEK 2.93
52 Haftanın En Yüksek Seviyesi	SEK 7.35
52 Haftanın En Düşük Seviyesi	SEK 2.93
Beta	-0.17
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	-58.19%
33 Yıllık Değişim	-64.70%
5 Yıllık Değişim	-84.69%
Halka arzdan bu yana değişim	-95.12%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0GP7	GB Biotechs	GB Pazar
7D	0%	2.0%	1.7%
1Y	-58.2%	-17.5%	8.3%

Getiri vs. Endüstri: 0GP7 geçen yıl % -17.5 oranında getiri sağlayan UK Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: 0GP7 geçen yıl % 8.3 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 0GP7's price volatile compared to industry and market?
0GP7 volatility
0GP7 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0GP7 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 0GP7 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1987	10	Jens Lindberg	www.medivir.com

Medivir AB (publ) Temel Bilgiler Özeti

Medivir'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0GP7 temel i̇stati̇sti̇kler
Piyasa değeri	SEK 348.84m
Kazançlar(TTM)	-SEK 96.52m
Gelir(TTM)	SEK 7.73m

45.1x

P/S Oranı

-3.6x

F/K Oranı

0GP7 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0GP7 gelir tablosu (TTM)
Gelir	SEK 7.73m
Gelir Maliyeti	SEK 76.47m
Brüt Kâr	-SEK 68.73m
Diğer Giderler	SEK 27.79m
Kazançlar	-SEK 96.52m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

Aug 22, 2024

Hisse başına kazanç (EPS)	-0.86
Brüt Marj	-888.81%
Net Kâr Marjı	-1,248.18%
Borç/Özkaynak Oranı	0%

0GP7 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0GP7 Stoklara Genel Bakış

Ödüller

Risk Analizi

Medivir AB (publ) Rakipler

AIM:ONC

UK£17.2m

AIM:OPTI

UK£12.2m

AIM:TRX

UK£40.6m

AIM:APTA

UK£6.5m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Recent updates

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility

Medivir Aktiebolag (publ) Approves Board Appointments

High number of new and inexperienced directors

Full year 2023 earnings released: kr1.48 loss per share (vs kr1.59 loss in FY 2022)

High number of new and inexperienced directors

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

High number of new and inexperienced directors

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.27 loss in 3Q 2022)

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

High number of new and inexperienced directors

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Medivir AB Announces Patent Application for Fostrox Approval in China

New major risk - Revenue size

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

Medivir AB (publ), Annual General Meeting, May 05, 2021

Medivir AB Announces Delisting of Paid Subscription Shares

Medivir AB Enters into Licensing Agreement with Ubiquigent Limited for Preclinical Program USP7

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Medivir AB (publ) Temel Bilgiler Özeti

45.1x

-3.6x

Kazanç ve Gelir